176 related articles for article (PubMed ID: 25071346)
21. Helicobacter pylori and cholesterol gallstone formation in C57L/J mice: a prospective study.
Maurer KJ; Rogers AB; Ge Z; Wiese AJ; Carey MC; Fox JG
Am J Physiol Gastrointest Liver Physiol; 2006 Jan; 290(1):G175-82. PubMed ID: 16109843
[TBL] [Abstract][Full Text] [Related]
22. Restoration of gallstone susceptibility by leptin in C57BL/6J ob/ob mice.
Hyogo H; Roy S; Cohen DE
J Lipid Res; 2003 Jun; 44(6):1232-40. PubMed ID: 12671032
[TBL] [Abstract][Full Text] [Related]
23. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice.
Matsumoto K; Imasato M; Yamazaki Y; Tanaka H; Watanabe M; Eguchi H; Nagano H; Hikita H; Tatsumi T; Takehara T; Tamura A; Tsukita S
Gastroenterology; 2014 Nov; 147(5):1134-45.e10. PubMed ID: 25068494
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of hepatic microsomal triglyceride transfer protein protects mice from diet-induced gallstones.
Amigo L; Castro J; Miquel JF; Zanlungo S; Young S; Nervi F
Gastroenterology; 2006 Dec; 131(6):1870-8. PubMed ID: 17064699
[TBL] [Abstract][Full Text] [Related]
25. CAV1 Prevents Gallbladder Cholesterol Crystallization by Regulating Biosynthesis and Transport of Bile Salts.
Xu G; Li Y; Jiang X; Chen H
J Cell Biochem; 2016 Sep; 117(9):2118-27. PubMed ID: 26875794
[TBL] [Abstract][Full Text] [Related]
26.
Xie Y; Cifarelli V; Pietka T; Newberry EP; Kennedy SM; Khalifeh-Soltani A; Clugston R; Atabai K; Abumrad NA; Davidson NO
J Lipid Res; 2017 Aug; 58(8):1692-1701. PubMed ID: 28634191
[TBL] [Abstract][Full Text] [Related]
27. Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.
Tharp KM; Khalifeh-Soltani A; Park HM; Yurek DA; Falcon A; Wong L; Feng R; Atabai K; Stahl A
Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(10):G855-64. PubMed ID: 27033116
[TBL] [Abstract][Full Text] [Related]
28. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.
Wang HH; Portincasa P; Wang DQ
Eur J Clin Invest; 2016 Feb; 46(2):158-69. PubMed ID: 26683129
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin and integrin are involved in cholesterol gallstone formation.
Yang L; Chen JH; Cai D; Wang LY; Zha XL
Med Sci Monit; 2012 Jan; 18(1):BR16-23. PubMed ID: 22207105
[TBL] [Abstract][Full Text] [Related]
30. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
31. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
Kim JK; Cho SM; Kang SH; Kim E; Yi H; Yun ES; Lee DG; Cho HJ; Paik YH; Choi YK; Haam SJ; Shin HC; Lee DK
J Gastroenterol Hepatol; 2012 Nov; 27(11):1745-51. PubMed ID: 22849613
[TBL] [Abstract][Full Text] [Related]
32. Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice.
Xu G; Zhao L; Fuchs M
Chin Med J (Engl); 2002 Sep; 115(9):1292-5. PubMed ID: 12411097
[TBL] [Abstract][Full Text] [Related]
33. Polymorphism and Expression Profile of Cholecystokinin Type A Receptor in Relation to Gallstone Disease Susceptibility.
Kazmi HR; Chandra A; Nigam J; Baghel K; Srivastava M; Maurya SS; Parmar D
Biochem Genet; 2016 Oct; 54(5):665-75. PubMed ID: 27287528
[TBL] [Abstract][Full Text] [Related]
34. Cholangiocyte bile salt transporters in cholesterol gallstone-susceptible and resistant inbred mouse strains.
Liu JJ; Glickman JN; Masyuk AI; Larusso NF
J Gastroenterol Hepatol; 2008 Oct; 23(10):1596-602. PubMed ID: 18717763
[TBL] [Abstract][Full Text] [Related]
35. Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice.
Lee BJ; Kim JS; Kim BK; Jung SJ; Joo MK; Hong SG; Kim JS; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT; Yoo HS; Oh S
J Gastroenterol Hepatol; 2010 Jun; 25(6):1105-10. PubMed ID: 20594226
[TBL] [Abstract][Full Text] [Related]
36. Ezetimibe prevents cholesterol gallstone formation in mice.
Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
[TBL] [Abstract][Full Text] [Related]
37. Transgenic overexpression of Niemann-Pick C2 protein promotes cholesterol gallstone formation in mice.
Acuña M; González-Hódar L; Amigo L; Castro J; Morales MG; Cancino GI; Groen AK; Young J; Miquel JF; Zanlungo S
J Hepatol; 2016 Feb; 64(2):361-369. PubMed ID: 26453970
[TBL] [Abstract][Full Text] [Related]
38. Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet.
Amigo L; Quiñones V; Mardones P; Zanlungo S; Miquel JF; Nervi F; Rigotti A
Gastroenterology; 2000 Apr; 118(4):772-9. PubMed ID: 10734029
[TBL] [Abstract][Full Text] [Related]
39. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
Wang HH; Portincasa P; Mendez-Sanchez N; Uribe M; Wang DQ
Gastroenterology; 2008 Jun; 134(7):2101-10. PubMed ID: 18442485
[TBL] [Abstract][Full Text] [Related]
40. Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice.
Xie Y; Fung HY; Newberry EP; Kennedy S; Luo J; Crooke RM; Graham MJ; Davidson NO
J Lipid Res; 2014 Mar; 55(3):540-8. PubMed ID: 24474819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
